Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

October 29, 2019

Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 22, 2019

Harpoon Therapeutics Announces Presentation on HPN328 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

August 28, 2019

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

August 5, 2019

Harpoon Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

July 31, 2019

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

May 9, 2019

Harpoon Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

April 18, 2019

Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers

March 14, 2019

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

March 13, 2019

Harpoon Therapeutics to Participate in Upcoming William Blair Cancer Immunotherapy Conference

March 7, 2019

Harpoon Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2021. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations